Product logins

Find logins to all Clarivate products below.


Neuropathic pain can develop after nerve lesions form at any level of the somatosensory nervous system, peripheral or central; the precise mechanisms that generate pain post-nerve injury are not wholly understood. Such complexity makes it difficult for physicians to diagnose and, consequently, determine an effective treatment for each patient. Primary care physicians and neurologists prescribe therapies from several drug classes, including antiepileptic drugs, antidepressants, NSAIDs, dual-acting opioid analgesics, and opioid analgesics, largely in an escalating sequence to provide patients with adequate analgesia, each of whom may respond differently to the therapies. Antiepileptic drugs and antidepressants are the patient-share leaders in treating neuropathic pain; opioid analgesics are reserved for later-line use for severe or unmanageable pain. Recent efforts in the United States have been implemented to curb the overprescription of opioid analgesics and thus reduce the risk of abuse/misuse associated with these therapies, efforts that are not expected to have much impact in the near future on prescribing of this drug class for neuropathic pain patients. The Current Treatment Overview provides insight into how neuropathic pain is treated and managed today, while the detailed, expanded analysis explores how U.S. primary care physicians and neurologists are treating neuropathic pain and the factors behind their treatment decisions.

Related Market Assessment Reports

Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications…
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
Report
Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or functional loss of melanocytes. Given its visible manifestations, the disease is associated with a substantial…
Report
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
The treatment landscape for ulcerative colitis (UC) is rapidly evolving. TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s…